Bioxodes

Rue Santos-Dumont, 1
6041 GOSSELIES
Belgium

[email protected] +32 71 23 96 00 bioxodes.com

Type
- Company
Application domains
- Biopharma
Core business
- R&D
Technology
- Biologics
- Small molecule
Therapeutic area
- Neurology

Bioxodes is a clinical stage company developing a first-in-class drug candidate, Ir-CPI, for the prevention of thrombosis and neuroinflammation in haemorrhagic stroke patients.

Related news

News

Bioxodes-brain-image2

Bioxodes announces positive Phase 2a interim data for BIOX-101 in intracerebral hemorrhagic stroke patients

Bioxodes obtains Orphan Drug Designation for hemorrhagic stroke therapeutic candidate in US and Europe

bioxodes2

Bioxodes secures new funds to reach early 2025 milestones and pursue Series B financing

All member's news